Patients with Multiple Myeloma on Anti-CD38 or Anti-BCMA Based Regimens and Patients with Waldenstrom's Macroglobulinemia Under Rituximab or BTK Inhibitors Have a Poor Humoral Response Following COVID-19 Vaccination

Introduction: Recent data suggest a suboptimal antibody response to COVID-19 vaccination in patients with hematological malignancies. Herein, we evaluated the development of neutralizing antibodies (NAbs) against SARS-CoV-2 in patients with plasma cell neoplasms (PCNs) after vaccination with either...

Descripción completa

Detalles Bibliográficos
Autores principales: Terpos, Evangelos, Gavriatopoulou, Maria, Ntanasis-Stathopoulos, Ioannis, Briasoulis, Alexandros, Gumeni, Sentiljana, Malandrakis, Panagiotis, Fotiou, Despina, Papanagnou, Eleni-Dimitra, Migkou, Magdalini, Theodorakakou, Foteini, Roussou, Maria, Eleutherakis-Papaiakovou, Evangelos, Kanellias, Nikolaos, Trougakos, Ioannis P., Kastritis, Efstathios, Dimopoulos, Meletios-Athanasios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
652.Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701567/
http://dx.doi.org/10.1182/blood-2021-144856

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701567/
http://dx.doi.org/10.1182/blood-2021-144856

Ejemplares similares